SCHEMBL533099

SCHEMBL533099

Cc1cc(C)c(C2CCCC2)cc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
TDO2 P48775 2/20 0.37
PSMB5 P28074 1/20 0.37
ALDH1A1 P00352 4/20 0.34
HSD17B10 Q99714 2/20 0.34
CYP1A2 P05177 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP7 P55210 1/20 0.34
HIF1A Q16665 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR2A P28223 2/20 0.33
TERT O14746 1/20 0.33
TDP1 Q9NUW8 2/20 0.32
CASP1 P29466 1/20 0.32
JAK2 O60674 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533769 0.98 CYP3A4 (0.44) CYP3A4TSHRMAPK1TDO2PSMB5
SCHEMBL9819248 0.83 CYP3A4 (0.41) CYP3A4TSHRMAPK1TDO2PSMB5
SCHEMBL10788453 0.82 PSMB5 (0.44) TDO2PSMB5KDM4EMEN1MAPT
SCHEMBL8735825 0.80 PSMB5 (0.43) TDO2PSMB5KDM4EMEN1MAPT
SCHEMBL9167795 0.80 PSMB5 (0.46) TDO2PSMB5KDM4EMEN1MAPT
SCHEMBL962513 0.79 NUDT1 (0.41) CYP3A4TSHRMAPK1TDO2PSMB5
SCHEMBL4568235 0.78 KDM1A (0.41) CYP3A4TSHRMAPK1ALDH1A1MEN1
SCHEMBL5559715 0.76 HTR2C (0.31)
SCHEMBL11705549 0.75 KDM4E (0.38) CYP3A4MAPK1PSMB5ALDH1A1HSD17B10
SCHEMBL13569777 0.75 CYP3A4 (0.41) CYP3A4TSHRMAPK1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415760-A2 CCR-9 antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2012-02-08 EP disclosed
US-7579340-B2 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists PFIZER INC (US) 2009-08-25 US disclosed
US-7319111-B2 Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-01-15 US disclosed
US-20070293503-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS, INC. 2007-12-20 US disclosed
US-7288538-B2 Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation ENCYSIVE PHARMACEUTICALS, INC. (US) 2007-10-30 US disclosed
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS INC. 2005-03-03 US disclosed
US-20040180892-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists ENCYSIVE PHARMACEUTICALS INC. 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049286-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 CYP3A4 4199/4885TSHR 1741/4885MAPK1 2363/4885
US-20040180892-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 CYP3A4 4199/4885TSHR 1741/4885MAPK1 2363/4885
US-20070293503-A1 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists CCR9, CCR1, CCRL2 CYP3A4 4199/4885TSHR 1741/4885MAPK1 2363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.